Jake, I had a request to send this related to Duke, PS Targeting and Immunolight and to remind that Takuya Osada, Zachary Hartman and Kim Lyerly now have Scott Antonia at Duke just left Moffitt last year. We were skeptical at first—not anymore since Keytruda patients MOS was enhanced via Bavituximab but even investigative reporters in some places are organizing due to the scope of how much information has been blocked in the past. This investigation that we have with Thousand Talents took us down the rabbit hole that led to Intellectual Property rights of PS Targeting and I am surprised at the amount of information on this board.
Through a partnership with Duke University and a team of over thirty scientists, physicians and engineers, led by President Harold Walder, Immunolight is advancing the platform technology by innovating tiny particles that absorb energies that can penetrate tissue and converting them into ultraviolet light inside a tumor to activate psoralen, a known anti-cancer drug.
"Our highest priority is to translate this amazing science into an actual cancer treatment in patients," Walder said. "I think we are quite close."
Immunolight technology has the potential to create a dramatic shift in the treatment of cancer. It wasn't that long ago that the treatments were limited to three options that included chemotherapy, radiation and surgery. Although improvements have been made in all three areas, cancer remains one of the most grueling diseases that afflict us today in ways that influence us emotionally, physically and financially.
"We have enjoyed a highly productive collaboration with the scientists at Duke and are encouraged by the effects we have seen in cells and in preliminary animal studies. We look forward to moving the technology ahead into patients as a promising new approach to treating solid tumors," said founder and CEO Rick Bourke.
When can we expect to see Immunolight's technology trials begin on people? According to Walder, "discussions have begun with the FDA about the requirements to initiate the first human clinical trial."
"We are honored to be chosen as the most innovative company by Crain's Detroit Business News," Walder said, "It is our hope that we can provide an alternative treatment in the fight against cancer with a non-invasive, immune-based treatment that doesn't involve the cytotoxic agents used in chemotherapy."
Psoralen and Ultraviolet A Light Treatment Directly Affects Phosphatidylinositol 3-Kinase Signal Transduction by Altering Plasma Membrane Packing*
Article information
J Biol Chem. 2016 Nov 18; 291(47): 24364–24376. Published online 2016 Sep 29. doi: 10.1074/jbc.M116.735126 PMCID: PMC5114394 PMID: 27687726 Britt Van Aelst,‡ Rosalie Devloo,‡ Pierre Zachée,§ Ruben t'Kindt,¶ Koen Sandra,¶ Philippe Vandekerckhove,?**‡‡ Veerle Compernolle,‡?‡‡ and Hendrik B. Feys‡,1 From the ‡Transfusion Research Center, Belgian Red Cross-Flanders, 9000 Ghent, Belgium, the §Department of Hematology, Hospital Network Antwerp, 2000 Antwerp, Belgium, the ¶Research Institute for Chromatography, 8500 Kortrijk, Belgium, the ?Blood Service of the Belgian Red Cross-Flanders, 2800 Mechelen, Belgium, the **Department of Public Health and Primary Care, KULeuven, 3000 Leuven, Belgium, and the ‡‡Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium 1 To whom correspondence should be addressed: Transfusion Research Center, Belgian Red Cross-Flanders, Ottergemsesteenweg 413, 9000 Ghent, Belgium., Tel.: 32-9-244-56-58; E-mail: eb.siurkedor@syef.kirdneh. Edited by George Carman Received 2016 Apr 27; Revised 2016 Sep 17
___________
Michael Gray Jian Gong Van Nguyen Jeff Hutchins Bruce Freimark
Poster Presentation Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771 Michael Gray1, Jian Gong1, Van Nguyen1, Takuya Osada2, Zachary Hartman2, Jeff Hutchins1, Bruce Freimark1 and Kim Lyerly2 Author affiliations grid.430202.7Peregrine Pharmaceuticals Inc.Tustin CA USA grid.26009.3d0000000419367961Duke University Durham NC USA
__________
Patents by Inventor Takuya Osada Takuya Osada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
X-RAY PSORALEN ACTIVATED CANCER THERAPY (X-PACT) Publication number: 20200009398 Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug. Type: Application Filed: August 29, 2019 Publication date: January 9, 2020 Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY Inventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Frederic A. BOURKE, JR., Harold WALDER, Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
Vaccines against HER3 antigens and methods of using the same Patent number: 10487143 Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon HER2-mediated signaling. Type: Grant Filed: October 5, 2017 Date of Patent: November 26, 2019 Assignee: Duke University Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman X-ray psoralen activated cancer therapy (X-PACT) Patent number: 10441810 Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug. Type: Grant Filed: February 16, 2017 Date of Patent: October 15, 2019 Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder, Frederic A. Bourke, Jr., Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada CANCER VACCINES AND METHODS OF DELIVERY Publication number: 20190022204 Abstract: Disclosed are compositions, methods, and kits for treating a cancer or pre-cancer. In particular, the invention generally relates to cancer vaccines as well as methods of delivering the vaccines. Combination treatments including the vaccines in combination with immunomodulatory agents are also contemplated. Type: Application Filed: January 9, 2017 Publication date: January 24, 2019 Applicant: DUKE UNIVERSITY Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME Publication number: 20180344824 Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent. Type: Application Filed: July 25, 2018 Publication date: December 6, 2018 Applicant: Duke University Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman X-RAY PSORALEN ACTIVATED CANCER THERAPY (X-PACT) WITH ASSOCIATED TREATMENTS Publication number: 20180344850 Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body. Type: Application Filed: May 30, 2018 Publication date: December 6, 2018 Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY Inventors: Frederic A. BOURKE, JR., Mark DEWHIRST, Neil SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA, Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER
VACCINES AGAINST AN ONCOGENIC ISOFORM OF ESR1 AND METHODS OF USING THE SAME Publication number: 20180326030 Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided. Type: Application Filed: July 24, 2018 Publication date: November 15, 2018 Applicant: Duke University Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
VACCINES AGAINST ANTIGENS INVOLVED IN THERAPY RESISTANCE AND METHODS OF USING SAME Publication number: 20180311329 Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polyepptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided. Type: Application Filed: April 25, 2018 Publication date: November 1, 2018 Applicant: Duke University Inventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman HER3 VACCINE VECTOR COMPOSITIONS AND METHODS OF USING THE SAME Publication number: 20180282736 Abstract: The present inventors provide HER3 vaccine vector compositions and methods of using the same. More specifically, the present inventors demonstrate, in part, that a combination of HER3 vaccine vectors with checkpoint inhibitors suppresses or eliminates cancer cells more effectively than either alone. Type: Application Filed: April 2, 2018 Publication date: October 4, 2018 Applicant: Duke University Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
Vaccines against antigens involved in therapy resistance and methods of using same Patent number: 9956276 Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided. Type: Grant Filed: January 21, 2013 Date of Patent: May 1, 2018 Assignee: Duke University Inventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
VACCINES AGAINST HER3 ANTIGENS AND METHODS OF USING THE SAME Publication number: 20180094050 Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon HER2-mediated signaling. Type: Application Filed: October 5, 2017 Publication date: April 5, 2018 Applicant: Duke University Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman VACCINES AGAINST AN ONCOGENIC ISOFORM OF ESR1 AND METHODS OF USING THE SAME Publication number: 20170196952 Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided. Type: Application Filed: July 7, 2015 Publication date: July 13, 2017 Applicant: Duke University Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME Publication number: 20170196953 Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent. Type: Application Filed: July 7, 2015 Publication date: July 13, 2017 Applicant: Duke University Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
X-RAY PSORALEN ACTIVATED CANCER THERAPY (X-PACT) Publication number: 20170157418 Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug. Type: Application Filed: February 16, 2017 Publication date: June 8, 2017 Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY Inventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER, Frederic A. BOURKE, JR., Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA Compositions And Methods For Modulating And Redirecting Immune Responses Publication number: 20170015758 Abstract: Provided herein are methods of modulating and redirecting an immune response. Compositions and methods for killing targeted cells in a cell population are also provided wherein, a cell population containing target cells expressing a target associated antigen and T cells are contacted with 1, 2, or more immune checkpoint antagonists and a multispecific T cell-redirecting agent that specifically binds the target associated antigen expressed on the target cells and specifically binds a T cell surface antigen. Type: Application Filed: January 21, 2015 Publication date: January 19, 2017 Inventors: Scott A. HAMMOND, Michael A. MORSE, Takuya OSADA, Herbert Kim LYERLY
VACCINES AGAINST ANTIGENS INVOLVED IN THERAPY RESISTANCE AND METHODS OF USING SAME Publication number: 20140377261 Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided. Type: Application Filed: January 21, 2013 Publication date: December 25, 2014 Applicant: Duke University Inventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
News 
Market Data 
Discover 
AI
